Term ended no later than Jul 15, 2025 · Medium confidence
20-year base term ended Jul 15, 2025
Held by Curia Global, Inc.
Filed May 2, 2014 as application 14/268,753 · Granted Jul 21, 2015
Base term, 20 years from filing
Today
Ended no later than Jul 15, 2025
2005
2026
Clock starts
Jul 15, 2005
Jul 15, 2005
Ended no later than
Jul 15, 2025
Jul 15, 2025
Granted
Jul 21, 2015
Jul 21, 2015
base term
after the term ends
fee events
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
Unresolved
Terminal disclaimer
On file, reference document not resolved, so the date above is an upper bound. We do not guess the cap.
2 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
6
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jul 15, 2005, when application 11/183,066, the earliest non-provisional in its chain, was filed (this one was filed May 2, 2014) | Jul 15, 2025 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 2 maintenance fees paid | term ended | High confidence |
| Computed term end | The steps above, in order | no later than Jul 15, 2025 | Medium confidence |
This family
| US 7,541,357 | Term ended Nov 2026 | Nov 2026 |
| US 8,227,486 | Term ended Nov 2026 | Nov 2026 |
| US 8,236,796 | Term ended Nov 2026 | Nov 2026 |
| US 8,741,901 | Term ended Jul 2025 | Jul 2025 |
| US 9,085,531 | this patent no later than Jul 2025 | no later than Jul 2025 |
| US 9,499,531 | Term ended Jul 2025 | Jul 2025 |
Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Oct 24, 2014 Reel 34045, frame 951 | Albany Molecular Research, Inc.; Alo Acquisition LLC; Amri Burlington, Inc.; Amri Rensselaer, Inc.; Cedarburg Pharmaceuticals, Inc.; Oso Biopharmaceuticals Manufacturing, LLC | Barclays Bank PLC, as the Collateral Agent | Security Interest |
| Aug 5, 2015 Reel 36257, frame 914 | Albany Molecular Research, Inc.; Amri Ssci, LLC | Barclays Bank PLC, as the Collateral Agent | Security Interest |
| Jun 22, 2016 Reel 39116, frame 827 | Bristol-Myers Squibb Company | Albany Molecular Research, Inc. | Assignment of Assignor's Interest |
| Aug 31, 2017 Reel 43742, frame 85 | Barclays Bank PLC, as Collateral Agent | Albany Molecular Research, Inc.; Alo Acquisition LLC; Amri Burlington, Inc.; Amri Rensselaer, Inc.; Cedarburg Pharmaceuticals, Inc.; Oso Biopharmaceuticals Manufacturing, LLC; Amri Ssci, LLC; Euticals Inc. | Release of Security Interest |
| Aug 31, 2017 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Albany Molecular Research, Inc. | Release of Security Interest |
| Aug 31, 2017 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Alo Acquisition LLC | Release of Security Interest |
| Aug 31, 2017 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Amri Burlington, Inc. | Release of Security Interest |
| Aug 31, 2017 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Amri Rensselaer, Inc. | Release of Security Interest |
| Aug 31, 2017 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Cedarburg Pharmaceuticals, Inc. | Release of Security Interest |
| Aug 31, 2017 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Oso Biopharmaceuticals Manufacturing, LLC | Release of Security Interest |
| Aug 31, 2017 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Amri Ssci, LLC | Release of Security Interest |
| Aug 31, 2017 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Euticals Inc. | Release of Security Interest |
| Sep 1, 2017 Reel 43746, frame 621 | Albany Molecular Research, Inc.; Amri Burlington, Inc.; Cedarburg Pharmaceuticals, Inc.; Euticals Inc.; Oso Biopharmaceuticals Manufacturing, LLC-by Its Sole Member: Alo Acquisition LLC | Barclays Bank, PLC as Collateral Agent | First Lien Security Agreement |
| Sep 1, 2017 Reel 43746, frame 657 | Albany Molecular Research, Inc.; Amri Burlington, Inc.; Cedarburg Pharmaceuticals, Inc.; Euticals Inc.; Oso Biopharmaceuticals Manufacturing LLC-by Its Sole Member:alo Acquisition LLC | Morgan Stanley Senior Funding, Inc. | Second Lien Security Agreement |
| Aug 14, 2018 Reel 46796, frame 352 | Albany Molecular Research, Inc.; Alo Acquisition LLC; Amri Burlington, Inc.; Amri Rensselaer, Inc.; Cedarburg Pharmaceuticals, Inc.; Oso Biopharmaceuticals Manufacturing, LLC | Barclays Bank PLC, as the Collateral Agent | Corrective Assignment to Correct the Incorrect Patent No. 7541537 Previously Recorded at Reel: 034045 Frame: 0951. Assignor(S) Hereby Confirms the Security Interest. |
| Oct 29, 2020 Reel 54252, frame 687 | Morgan Stanley Senior Funding, Inc., as Collateral Agent | Albany Molecular Research, Inc.; Amri Burlington, Inc.; Cedarburg Pharmaceuticals, Inc.; Euticals Inc.; Oso Biopharmaceuticals Manufacturing, LLC | Release of Security Interest |
| Oct 29, 2020 reel/frame not recorded | Morgan Stanley Senior Funding, Inc., as Collateral Agent | Albany Molecular Research, Inc. | Release of Security Interest |
| Oct 29, 2020 reel/frame not recorded | Morgan Stanley Senior Funding, Inc., as Collateral Agent | Amri Burlington, Inc. | Release of Security Interest |
| Oct 29, 2020 reel/frame not recorded | Morgan Stanley Senior Funding, Inc., as Collateral Agent | Cedarburg Pharmaceuticals, Inc. | Release of Security Interest |
| Oct 29, 2020 reel/frame not recorded | Morgan Stanley Senior Funding, Inc., as Collateral Agent | Euticals Inc. | Release of Security Interest |
| Oct 29, 2020 reel/frame not recorded | Morgan Stanley Senior Funding, Inc., as Collateral Agent | Oso Biopharmaceuticals Manufacturing, LLC | Release of Security Interest |
| Nov 16, 2020 Reel 54382, frame 326 | Barclays Bank PLC, as Collateral Agent | Albany Molecular Research, Inc. | Release of Security Interest |
| Mar 7, 2025 Reel 70442, frame 908 | Curia Global, Inc.; Curia IP Holdings, LLC; Curia Bio, Inc. | Apollo Administrative Agency LLC | Security Interest |
| May 20, 2025 Reel 71298, frame 97 | Albany Molecular Research, Inc. | Curia Global, Inc. | Change of Name |
| Jun 3, 2025 Reel 71490, frame 880 | Apollo Administrative Agency LLC | Curia Global, Inc. | Partial Release of First Lien Intellectual Property Security Agreement Supplement |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Note
A terminal disclaimer is on file and its reference is not resolved. No cap is applied and none is guessed
Open question
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than Jul 15, 2025. We will not guess the cap.
Citations
0
later US patents cite this one
That is below the median of utility patents granted in 2015 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
This computed term ends no later than the date shown; an unresolved terminal disclaimer may end it earlier. Related patents and pending applications may cover overlapping subject matter.